Therapeutic Spectrum

Full Strategic Pipeline

ACA Therapeutics is a clinical-stage biopharmaceutical company leveraging its proprietary Upstream–Midstream–Downstream (UMD) Framework to systematically address disease biology across multiple pathways. Our platform is designed to efficiently generate and prioritize therapeutic programs across oncology, neurology, metabolic, and rare diseases. Our pipeline reflects a prioritized development strategy, with a lead clinical program and a broad portfolio of indications supported by translational research and prepared for efficient advancement toward IND submission.

Learn More
Our Pipeline Photo

Lead Clinical Programs

  • ACA-001: Pancreatic Cancer — Phase I IND Cleared (Trial Ready)

  • Expanding Portfolio

    Beyond our lead program, ACA Therapeutics is advancing a broad portfolio of additional programs across oncology, metabolic, neurology, and rare diseases, each progressing toward IND submission. Individual programs will be announced as they reach key regulatory and development milestones.

Platform Advantage

The UMD Framework enables a systems-level approach by targeting upstream drivers, midstream signaling pathways, and downstream disease manifestations. This integrated strategy supports the efficient generation of multiple therapeutic programs and allows flexible prioritization for clinical development and partnership opportunities.

By restoring upstream immune‑metabolic balance, our platform is designed to complement existing therapies, enabling lower doses, reduced treatment burden, and improved long‑term outcomes.

This upstream‑reset approach reduces the biological pressure that drives chronic, lifelong treatment dependence. By stabilizing immune, metabolic, and neuro‑inflammatory networks at their source, the platform has the potential to transform many current “forever medications” into time‑limited, lower‑intensity regimens—enhancing safety, lowering cost, and expanding therapeutic possibilities across rare and complex diseases.

Scroll to Top